COPD Therapeutics in Asia-Pacific Markets to 2022
Report Description
Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing.
COPD occurs most often in older people, but can also affect people in their middle ages.
It is a major cause of chronic morbidity and mortality globally. Many people suffer from this disease for years, and die from it or its complications, and it constitutes a substantial economic and social burden.
Globally, the COPD burden is projected to increase in the coming decades because of continued exposure to COPD risk factors, and the increasing number of smokers. Increased smoking will result in a greater number of people living with the condition, thereby acting as a driver for revenue growth.
GET 20% DISCOUNT ON THIS REPORT
Continued…
Scope • Bronchodilators and ICS dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the COPD market? • Do branded therapies show continuous growth, and are they facing any competition from generics? • How will branded therapies be affected by upcoming pipeline therapies? • The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-inclass therapies. • Which molecular targets appear most frequently in the pipeline?
Download Report Sample @
https://www.24marketreports.com/request-sample/copd therapeutics-in-asia-pacific-markets-to-2022---growt
Table of content 1 Table of Contents 5 1.1 List of Tables 8 1.2 List of Figures 8 2 Introduction 10 2.1 Disease Introduction 10 2.2 Epidemiology 10 2.3 Symptoms 11 2.4 Etiology and Pathophysiology 12 3 Marketed Products 18 3.1 Overview 18 3.2 Bronchodilator Combination Therapy 18
Visit us at : https://www.24marketreports.com/life-sciences/cop d-therapeutics-in-asia-pacific-markets-to-2022--growth-driven-by-rising-prevalence-growing-awaren ess-and-expected-launch-of-novel-therapies
Stay With Us:
TELEPHONE: (+1) 646 781 7170 Email: help@24marketreports.com
New York City Zone 01, United States,.